Brenus Pharma announced that new first-in-human data will be presented at the AACR Annual Meeting 2026 (April 17-22, San Diego, California). The company continues to advance its lead candidate, STC-1010, a next generation in vivo allogeneic immunotherapy built on the Stimulated Ghost Cells (SGC) technology.
The poster will provide a translational overview demonstrating how STC-1010 is administrated in microsatellite-stable colorectal cancer (MSS CRC), a setting resistant to standards immunotherapy
Clinical findings from BreAK CRC001 (NCT06934538), Phase I/IIa first-in-human evaluation of STC-1010 in unresectable metastatic MSS CRC, first-line setting (n=6; median follow-up: 6 months) show
- Favorable safety with no dose-limiting toxicities (DLTs) observed.
- Promising early efficacy, including 100% disease control rate (DCR) in RECIST
- Evidence of immune activation, including delayed-type hypersensitivity (DTH) responses.
Exploratory analyses are ongoing to further characterize tumor-immune dynamics and identify predictive biomarkers supporting subsequent stages of clinical development.
Together, these results support continued advancement of STC-1010 toward later-stage evaluation and validate the SGC technology as a scalable, "off-the-shelf" approach for high unmet-need solid tumors.
Poster Details
- Poster Title: "From preclinical models to first-in-human evaluation of STC-1010 immunotherapy in unresectable advanced colorectal cancer"
- Session: First-in-Human Phase I Clinical Trials
- Date Time: April 20, 2026 9:00 AM 12:00 PM
- Location: Poster Section 50
- Poster Board Number: 11
- Abstract Number: CT051
Authors: Diego TOSI 1, Antoine ITALIANO 2, Antoine HOLLEBECQUE 3, Benoît YOU 4, Iseulys RICHERT 5, Benoit PINTEUR 5, Paul BRAVETTI 5, François GHIRINGHELLI 6
1 Montpellier Cancer Institute, Montpellier, France; 2 Bergonié Institute, Bordeaux, France; 3 Gustave Roussy Institute, Villejuif, France; 4 Hospices Civils de Lyon, Pierre-Bénite, France; 5 Brenus Pharma, Lyon, France 6Georges-François Leclerc Cancer Center, Dijon, France
About Brenus Pharma
Brenus Pharma develops an off-the-shelf platform advancing novel modalities in immuno-oncology. This cutting-edge precision technology mimics tumor protein expression and makes it visible to the immune system, enabling a multi-specific in vivo immune response adapting to tumor evolution in hard-to-treat solid tumors where current therapies fall short.
www.brenus-pharma.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260414465808/en/
Contacts:
contact@brenus-pharma.com
